Pharmidex moves onto the Stevenage Bioscience Catalyst campus
Modern facilities encourage dialogue and interaction between companies and researchers on the site
The UK's Nanotechnology Knowledge Transfer Network (NanoKTN) has helped Pharmidex, one of its members, secure new facilities at the Stevenage Bioscience Catalyst, the UK's first open innovation bioscience campus.
Stevenage Bioscience Catalyst (SBC) offers state-of-the-art facilities that are pre-fitted and ready-for-science. The layout of the campus is designed to encourage co-operation, dialogue and interaction between tenants and also with scientists on the GlaxoSmithKline R&D site.
'We attended the NanoKTN’s NanoMed mission in 2011 and discussed with NanoKTN staff our specialist requirement of bioscience laboratories for the company,' explained Mo Alavijeh, CEO at Pharmidex.
'Having successfully grown the company, we found ourselves running out of lab space at our old premises. The NanoKTN recommended the SBC and set up a meeting, which resulted in Pharmidex moving into its new facilities at SBC.'
Alavijeh added that the new laboratory at SBC not only offers state-of-the-art facilities, but also an exciting environment surrounded by similar innovative companies for potential collaboration.
Pharmidex provides bespoke integrated assessments of ADMET-PK/PD profiles of drug candidates for major pharma, biotechs, academics and medical charities worldwide. Founded in 2002, Pharmidex has expertise in the area of CNS and oncology medicines research.
